MRI in children given gadodiamide injection: Safety and efficacy in CNS and body indications

European Journal of Radiology

Volumn 23, Issue 3, 1996, Pages 190-196

  Lundby, Bjørg ^a   Gordon, Paul ^a   Hugo, Frank ^b  

^a NYCOMED IMAGING AS   (Norway)

^b NONE

Author keywords

children; efficacy; gadodiamide injection; gadopentetate dimeglumine; MRI; safety

Indexed keywords

GADODIAMIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0030294008     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0720-048X(96)01088-1     Document Type: Article

References (14)

1. [1] Wolf GL, Arenson RL, Cross AP. A prospective trial of ionic vs. nonionic contrast agents in routine clinical practice: comparison of adverse effects. Am J Radiol 1989; 152: 939-944.
2. [2] Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media: a report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175: 621-628.
3. [3] Ge HL, Hirsch WL, Wolf GL, Rubin RA, Hackett RK. Diagnostic role of gadolinium-DTPA in pediatric neuroradiology. A retrospective review of 655 cases. Neuroradiology 1992; 34: 122-125.
4. [4] Powers TA, Partain CL, Kessler RM, et al. Central nervous system lesions in pediatric patients: Gd-DTPA-enhanced MR imaging. Radiology 1988; 169: 723-726.
5. [5] Ball WS, Nadel SN, Zimmerman RA. et al. Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. Radiology 1993; 186: 769-774.
6. [6] Sze G, Brant-Zawadzki M, McNamara MT, et al. Use of the magnetic resonance contrast agent gadodiamide in the central nervous system. Results of a multicenter trial. Invest Radiol 1993; 28 (Suppl 1): S49-S55.
7. [7] Lundby B, Svaland MG, Gordon P, Aslanian V, Jonsson E, Catton D. Experience with gadodiamide injection (Omniscan) in clinical phase III trials. Clin MRI 1995: 5: S103-S108.
8. [8] Svaland MG, Lundby B, Kristoffersen DT. Comparison of the safety of the standard dose and a higher dose of gadodiamide injection for MR imaging of the central nervous system. J Magn Reson Imaging 1994; 4: 419-423.
9. [9] Lundby B, Berg KJ, Lien HH, Aamdal S. A double blind study to evaluate the tolerability of gadodiamide injection and its effect on renal function in patients undergoing cerebral magnetic resonance imaging. Br J Radiol 1993; 66: 871-876.
10. [10] Demaerel P, Marchal G, Wilms G, et al. Gadodiamide injection at 0.1 and 0.3 mmol/kg body weight: a phase III double-blind, parallel, randomised clinical investigation of known or suspected central nervous system lesions at 1.5T. Neuroradiology 1994; 36: 355-359.
11. [11] Sherwin PF, Hugo FP, Robison RO et al. Safety, tolerance, and pharmacokinetics of high doses of gadodiamide injection, a nonionic magnetic resonance imaging contrast agent. Acad Radiol 1994; 1 (Suppl 1): S2-S9.
12. [12] Latchaw RE, Safety and efficacy of gadodiamide injection administered intravenously to children for contrast-enhanced MR of the central nervous system. Acad Radiol 1994; 1 (Suppl 1): S15-S22.
13. [13] Valk J, Algra PR, Hazenberg CJ, Slooff WBM, Svaland MG. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 1993; 35: 173-177.
14. [14] Akeson P, Jonsson E, Haugen I, Holtås S. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 1995; 37: S229-S233.